Eyebot, a startup providing a 90-second imaginative and prescient take a look at kiosk that delivers doctor-verified glasses prescriptions, has secured $20 million in Collection A funding.
The Boston-based startup, based in 2021, streamlines how folks entry imaginative and prescient care by eliminating conventional obstacles, comparable to appointment delays, restricted accessibility, complicated insurance coverage necessities, and price.
Its kiosks, already present in malls, universities, retail shops, pharmacies, grocery chains, colleges, and airports, ship a free, 90-second imaginative and prescient take a look at. In response to the corporate, every take a look at generates a prescription that’s then reviewed and permitted by licensed eye docs, guaranteeing quick, handy, and dependable prescriptions.
The brand new funding, which brings Eyebot’s complete funding to greater than $30 million, comes roughly a yr after the startup raised its seed spherical in June 2024. Since then, the startup has performed greater than 45,000 free imaginative and prescient exams and is on observe to ship over half one million yearly, it says.
“Since our seed spherical, the shift has been dramatic. We’ve gone from piloting to partnering with a few of the largest firms within the U.S., launching kiosks all around the nation, and delivering tens of hundreds of imaginative and prescient exams,” Matthias Hofmann, co-founder and CEO of Eyebot, advised TechCrunch. “Income is scaling and our group has doubled in measurement. Most significantly, we’ve confirmed the mannequin works: persons are utilizing Eyebot, docs are validating the outcomes, and retailers are excited in regards to the visitors it drives.”
What units Eyebot aside, Hofmann mentioned, is its mixture of comfort and medical assurance. Each take a look at is reviewed by a physician, and all prescriptions are issued underneath scientific supervision. If take a look at outcomes point out something uncommon, sufferers are referred for in-person, complete exams. That steadiness of velocity plus scientific oversight earns belief, he says.
“At our mall areas, we’ve seen stunning uptake from mother and father with children,” Hofmann mentioned. “They’ll cease between shops, attempt Eyebot — generally even whereas holding their children’ palms — and depart with a prescription in simply a few minutes.”
Techcrunch occasion
San Francisco
|
October 27-29, 2025
Convincing conventional eye care suppliers to embrace a tech-first method has confirmed troublesome. Early skepticism ran deep: docs frightened about accuracy, whereas sufferers questioned whether or not a course of so quick might be dependable, in accordance with Hofmann. He says that hesitancy eased as soon as suppliers discovered that have docs evaluate each outcome, many with greater than a decade of expertise.
Eyebot is within the early phases of commercialization. Its imaginative and prescient take a look at is obtainable free to customers, and if a prescription is required, one of many firm’s docs verifies it for a price. Moreover, the corporate leases its kiosks to optical retailers, eyewear manufacturers, and impartial practices.
With the Collection A, the corporate plans to scale kiosk deployment and broaden its group throughout product, scientific operations, and industrial development, the CEO mentioned.
The most recent spherical was led by Normal Catalyst and included participation from returning traders AlleyCorp, Baukunst, Village International, Humba Enterprise, Ravelin, and Ubiquity Ventures.
